The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin-Induced Ototoxicity in Children With Cancer

被引:70
作者
Yang, J. J. [1 ]
Lim, J. Y. S. [1 ,2 ]
Huang, J. [3 ]
Bass, J. [4 ]
Wu, J. [3 ]
Wang, C. [3 ]
Fang, J. [5 ]
Stewart, E. [6 ]
Harstead, E. H. [1 ]
Robinson, G. W. [6 ]
Evans, W. E. [1 ]
Pappo, A. [6 ]
Zuo, J. [5 ]
Relling, M. V. [1 ]
Onar-Thomas, A. [3 ]
Gajjar, A. [6 ]
Stewart, C. F. [1 ]
机构
[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pediat, Singapore 117595, Singapore
[3] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA
[4] St Jude Childrens Res Hosp, Dept Pediat Med, Memphis, TN 38105 USA
[5] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA
[6] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA
基金
美国国家卫生研究院;
关键词
THIOPURINE S-METHYLTRANSFERASE; HEARING-LOSS; RECEIVING CISPLATIN; MERCAPTOPURINE; IDENTIFICATION; CHEMOTHERAPY; RADIOTHERAPY; CONSENSUS; VARIANTS;
D O I
10.1038/clpt.2013.121
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ototoxicity is a debilitating side effect of platinating agents with substantial interpatient variability. We sought to evaluate the association of thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) genetic variations with cisplatin-related hearing damage in the context of frontline pediatric cancer treatment protocols. In 213 children from the St. Jude Medulloblastoma-96 and -03 protocols, hearing loss was related to younger age (P = 0.013) and craniospinal irradiation (P = 0.001), but did not differ by TPMT or COMT variants. Results were similar in an independent cohort of 41 children from solid-tumor frontline protocols. Functional hearing loss or hair cell damage was not different in TPMT knockout vs. wild-type mice following cisplatin treatment, and neither TPMT nor COMT variant was associated with cisplatin cytotoxicity in lymphoblastoid cell lines. In conclusion, our results indicated that TPMT or COMT genetic variation was not related to cisplatin ototoxicity in children with cancer and did not influence cisplatin-induced hearing damage in laboratory models.
引用
收藏
页码:252 / 259
页数:8
相关论文
共 32 条
[1]   Platinum-Induced Ototoxicity in Children: A Consensus Review on Mechanisms, Predisposition, and Protection, Including a New International Society of Pediatric Oncology Boston Ototoxicity Scale [J].
Brock, Penelope R. ;
Knight, Kristin R. ;
Freyer, David R. ;
Campbell, Kathleen C. M. ;
Steyger, Peter S. ;
Blakley, Brian W. ;
Rassekh, Shahrad R. ;
Chang, Kay W. ;
Fligor, Brian J. ;
Rajput, Kaukab ;
Sullivan, Michael ;
Neuwelt, Edward A. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (19) :2408-2417
[2]   Practical Grading System for Evaluating Cisplatin Ototoxicity in Children [J].
Chang, Kay W. ;
Chinosornvatana, Nina .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) :1788-1795
[3]   Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto- and Nephrotoxicity and Is a Target for Protective Interventions [J].
Ciarimboli, Giuliano ;
Deuster, Dirk ;
Knief, Arne ;
Sperling, Michael ;
Holtkamp, Michael ;
Edemir, Bayram ;
Pavenstaedt, Hermann ;
Lanvers-Kaminsky, Claudia ;
Zehnhoff-Dinnesen, Antoinette Am ;
Schinkel, Alfred H. ;
Koepsell, Hermann ;
Juergens, Heribert ;
Schlatter, Eberhard .
AMERICAN JOURNAL OF PATHOLOGY, 2010, 176 (03) :1169-1180
[4]   Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity [J].
Dolan, ME ;
Newbold, KG ;
Nagasubramanian, R ;
Wu, XL ;
Ratain, MJ ;
Cook, EH ;
Badner, JA .
CANCER RESEARCH, 2004, 64 (12) :4353-4356
[5]   A catechol-O-methyltransferase that is essential for auditory function in mice and humans [J].
Du, Xin ;
Schwander, Martin ;
Moresco, Eva Marie Y. ;
Viviani, Pia ;
Haller, Claudia ;
Hildebrand, Michael S. ;
Pak, Kwang ;
Tarantino, Lisa ;
Roberts, Amanda ;
Richardson, Heather ;
Koob, George ;
Najmabadi, Hossein ;
Ryan, Allen F. ;
Smit, Richard J. H. ;
Mueller, Ulrich ;
Beutler, Bruce .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (38) :14609-14614
[6]   Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity [J].
Filipski, K. K. ;
Mathijssen, R. H. ;
Mikkelsen, T. S. ;
Schinkel, A. H. ;
Sparreboom, A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (04) :396-402
[7]  
FONG RS, 1995, AM J OTOL, V16, P793
[8]   Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma [J].
Fouladi, Maryam ;
Chintagumpala, Murali ;
Ashley, David ;
Kellie, Stewart ;
Gururangan, Sridharan ;
Hassall, Tim ;
Gronewold, Lindsey ;
Stewart, Clinton F. ;
Wallace, Dana ;
Broniscer, Alberto ;
Hale, Gregory A. ;
Kasow, Kimberly A. ;
Merchant, Thomas E. ;
Morris, Brannon ;
Krasin, Matthew ;
Kun, Larry E. ;
Boyett, James M. ;
Gajjar, Amar .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3749-3755
[9]   A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma [J].
Furman, Wayne L. ;
McGregor, Lisa M. ;
McCarville, M. Beth ;
Onciu, Mihaela ;
Davidoff, Andrew M. ;
Kovach, Sandy ;
Hawkins, Dana ;
McPherson, Valerie ;
Houghton, Peter J. ;
Billups, Catherine A. ;
Wu, Jianrong ;
Stewart, Clinton F. ;
Santana, Victor M. .
INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) :1660-1670
[10]   Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial [J].
Gajjar, Amar ;
Chintagumpala, Murali ;
Ashley, David ;
Kellie, Stewart ;
Kun, Larry E. ;
Merchant, Thomas E. ;
Woo, Shaio ;
Wheeler, Greg ;
Ahern, Valerie ;
Krasin, Matthew J. ;
Fouladi, Maryam ;
Broniscer, Alberto ;
Krance, Robert ;
Hale, Gregory A. ;
Stewart, Clinton F. ;
Dauser, Robert ;
Sanford, Robert A. ;
Fuller, Christine ;
Lau, Ching ;
Boyett, James M. ;
Wallace, Dana ;
Gilbertson, Richard J. .
LANCET ONCOLOGY, 2006, 7 (10) :813-820